HKMPF (Hikma Pharmaceuticals) Institutional Ownership: 37.16% (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKMPF Hikma Pharmaceuticals PLC HKMPF
82 GF Score
Price $20.37
GF Value $27.87
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Institutional Ownership?

Hikma Pharmaceuticals HKMPF 82 Institutional Ownership is 37.16% as of Jul. 21, 2026. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $27.87 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Hikma Pharmaceuticals's institutional ownership is 37.16%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Hikma Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Hikma Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 0.00%.

Hikma Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Institutional Ownership Chart

Hikma Pharmaceuticals Historical Data

The historical data trend for Hikma Pharmaceuticals can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 42.90 43.81 44.50 44.66 43.71 41.93 41.16 41.41 41.21 40.87
HKMPF
82GF Score
Hikma Pharmaceuticals PLC HKMPF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 37.16% mean?
Hikma Pharmaceuticals (HKMPF) has a Institutional Ownership of 37.16% as of Jul. 21, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Institutional Ownership too high?
Hikma Pharmaceuticals' current Institutional Ownership is 37.16%. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Institutional Ownership compare to ZTS and UTHR?
Hikma Pharmaceuticals' Institutional Ownership of 37.16% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Institutional Ownership is 37.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.87, compared to a current price of $20.37 — trading 26.9% below its estimated fair value. The current Institutional Ownership is 37.16%. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Institutional Ownership is 37.16% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $20.37 is trading 26.9% below its estimated GF Value™ of $27.87. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPF:

  • Institutional Ownership: 37.16%
  • GF Value™: $27.87 vs. price of $20.37 (26.9% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score

Get the complete analysis for HKMPF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.37
Price
$27.87
GF Value